Jazz Pharmaceuticals: Promising Developments and Positive Data Reinforce Buy Rating

Ami Fadia, an analyst from Needham, maintained the Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated price target was raised to $202.00.

Ami Fadia has given her Buy rating due to a combination of factors that highlight Jazz Pharmaceuticals’ promising developments. The recent data updates presented at ASCO 2025 have shown positive incremental results, reinforcing the competitive edge of their product Zani in bile tract cancer (BTC) and its potential in gastroesophageal adenocarcinoma (GEA). Additionally, the potential approval and commercial viability of Zepzelca in first-line maintenance for small cell lung cancer (SCLC) further support this optimistic outlook.
Jazz Pharmaceuticals has reported significant progress in several key areas. The Phase 3 ImForte study data for lurbi plus atezo in first-line maintenance settings have demonstrated efficacy and safety, bolstering the case for approval. Moreover, updated Phase 2 data for Zanidatamab in first-line GEA showed impressive clinical outcomes, including a high objective response rate and extended median overall survival, compared to the current standard of care. Furthermore, survival outcomes for Zani in second-line BTC indicate a substantial clinical benefit, with a median overall survival significantly longer than the external control arm. These advancements collectively contribute to the positive assessment of Jazz Pharmaceuticals’ stock.

In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $147.00 price target.

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is neutral on the stock.